止血的管理和優化

Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T; CRASH-2 collaborators.

來源‎: Lancet 2011;377(9771):1096-101, 1101.e1-2.

檢索‎: PubMed 21439633

DOI碼‎: 10.1016/S0140-6736(11)60278-X

https://www.ncbi.nlm.nih.gov/pubmed/21439633 （開啟新視窗）

Antifibrinolytic drugs for acute traumatic injury. （開啟新視窗）

Roberts I, Shakur H, Ker K, Coats T; CRASH‐2 Trial collaborators.

來源‎: Cochrane Database Syst Rev 2011;(1):CD004896.

檢索‎: PubMed 21249666

DOI碼‎: 10.1002/14651858.CD004896.pub3

https://www.ncbi.nlm.nih.gov/pubmed/21249666 （開啟新視窗）

Use of tranexamic acid to reduce bleeding in burns surgery. （開啟新視窗）

Tang YM, Chapman TW, Brooks P

來源‎: J Plast Reconstr Aesthet Surg 2012;65(5):684-6.

檢索‎: PubMed 21983540

DOI碼‎: 10.1016/j.bjps.2011.09.028

https://www.ncbi.nlm.nih.gov/pubmed/21983540 （開啟新視窗）

Tranexamic acid reduced blood transfusions in acute burn surgery: a retrospective case-controlled trial. （開啟新視窗）

Tapking C, Hundeshagen G, Kirchner M, Fischer S, Kneser U, Bliesener B

來源‎: Burns. 2022;48(3):522-28.

檢索‎: PubMed 35339324

DOI碼‎: 10.1016/j.burns.2022.03.002

https://pubmed.ncbi.nlm.nih.gov/35339324/ （開啟新視窗）

重組活化凝血因子VII（rFVIIa）

Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery. （開啟新視窗）

Barua A, Rao VP, Ramesh B, Barua B, El-Shafei H.

來源‎: J Blood Med 2011;2:131-4.

檢索‎: PubMed 22287872

DOI碼‎: 10.2147/JBM.S21609

https://www.ncbi.nlm.nih.gov/pubmed/22287872 （開啟新視窗）

The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. （開啟新視窗）

Boffard KD, Choong PI, Kluger Y, Riou B, Rizoli SB, Rossaint R, Warren B; NovoSeven Trauma Study Group.

來源‎: Transfusion 2009;49 Suppl 5:240S-7S.

檢索‎: PubMed 19954486

DOI碼‎: 10.1111/j.1537-2995.2008.01987.x

https://www.ncbi.nlm.nih.gov/pubmed/19954486 （開啟新視窗）

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. （開啟新視窗）

Fries D

來源‎: Transfusion 2013;53 Suppl 1:91S-5S.

檢索‎: PubMed 23301979

DOI碼‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 （開啟新視窗）

A Jehovah's Witness with complex abdominal trauma and coagulopathy: use of factor VII and a review of the literature. （開啟新視窗）

Haan J, Scalea T

來源‎: Am Surg 2005;71(5):414-5.

檢索‎: PubMed 15986972

https://www.ncbi.nlm.nih.gov/pubmed/15986972 （開啟新視窗）

Results of the control trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. （開啟新視窗）

Hauser CJ, Boffard K, Dutton R, Bernard GR, Croce MA, Holcomb JB, Leppaniemi A, Parr M, Vincent JL, Tortella BJ, Dimsits J, Bouillon B; CONTROL Study Group.

來源‎: J Trauma 2010;69(3):489-500.

檢索‎: PubMed 20838118

DOI碼‎: 10.1097/TA.0b013e3181edf36e

https://www.ncbi.nlm.nih.gov/pubmed/20838118 （開啟新視窗）

Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. （開啟新視窗）

Hsia CC, Chin-Yee IH, McAlister VC.

來源‎: Ann Surg 2008;248(1):61-8.

檢索‎: PubMed 18580208

DOI碼‎: 10.1097/SLA.0b013e318176c4ec

https://www.ncbi.nlm.nih.gov/pubmed/18580208 （開啟新視窗）

Rescue treatment with recombinant factor VIIa is effective in patients with life-threatening bleedings secondary to major wound excision: a report of four cases. （開啟新視窗）

Johansson PI, Eriksen K, Alsbjørn B

來源‎: J Trauma 2006;61(4):1016-8.

檢索‎: PubMed 17033583

DOI碼‎: 10.1097/01.ta.0000239261.48022.f1

https://www.ncbi.nlm.nih.gov/pubmed/17033583 （開啟新視窗）

Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding. （開啟新視窗）

Kandane-Rathnayake RK, Isbister JP, Zatta AJ, Aoki NJ, Cameron P, Phillips LE; Australian and New Zealand Haemostasis Registry Steering Committee

來源‎: ANZ J Surg 2013;83(3):155-60.

檢索‎: PubMed 23035873

DOI碼‎: 10.1111/j.1445-2197.2012.06285.x

https://www.ncbi.nlm.nih.gov/pubmed/23035873 （開啟新視窗）

Recombinant factor VIIa in trauma patients with the 'triad of death.' （開啟新視窗）

Mitra B, Cameron PA, Parr MJ, Phillips L.

來源‎: Injury 2012;43(9):1409-14.

檢索‎: PubMed 21345431

DOI碼‎: 10.1016/j.injury.2011.01.033

https://www.ncbi.nlm.nih.gov/pubmed/21345431 （開啟新視窗）

Low-dose recombinant factor VIIa for trauma patients with coagulopathy. （開啟新視窗）

Stein DM, Dutton RP, Hess JR, Scalea TM.

來源‎: Injury 2008;39(9):1054-61.

檢索‎: PubMed 18656871

DOI碼‎: 10.1016/j.injury.2008.03.032

https://www.ncbi.nlm.nih.gov/pubmed/18656871 （開啟新視窗）

Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (Novoseven®). （開啟新視窗）

Tanaka KA, Waly AA, Cooper WA, Levy JH.

來源‎: Anesthesiology 2003;98(6):1513-5.

檢索‎: PubMed 12766668

https://www.ncbi.nlm.nih.gov/pubmed/12766668 （開啟新視窗）

凝血因子濃縮劑

Alternatives to allogeneic platelet transfusion. （開啟新視窗）

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

來源‎: Br J Haematol 2016;175(3):381-92.

檢索‎: PubMed 27650431

DOI碼‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 （開啟新視窗）

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. （開啟新視窗）

Fries D

來源‎: Transfusion 2013;53 Suppl 1:91S-5S.

檢索‎: PubMed 23301979

DOI碼‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 （開啟新視窗）

Plasma fibrinogen level on admission to the intensive care unit is a powerful predictor of postoperative bleeding after cardiac surgery with cardiopulmonary bypass. （開啟新視窗）

Kindo M, Hoang Minh T, Gerelli S, Perrier S, Meyer N, Schaeffer M, Bentz J, Announe T, Mommerot A, Collange O, Pottecher J, Cristinar M, Thiranos JC, Gros H, Mertes PM, Billaud P, Mazzucotelli JP

來源‎: Thromb Res 2014;134(2):360-8.

檢索‎: PubMed 24857189

DOI碼‎: 10.1016/j.thromres.2014.05.008

https://www.ncbi.nlm.nih.gov/pubmed/24857189 （開啟新視窗）